CN114599368A - 四环化合物及其盐、组合物以及其使用方法 - Google Patents

四环化合物及其盐、组合物以及其使用方法 Download PDF

Info

Publication number
CN114599368A
CN114599368A CN202080069508.0A CN202080069508A CN114599368A CN 114599368 A CN114599368 A CN 114599368A CN 202080069508 A CN202080069508 A CN 202080069508A CN 114599368 A CN114599368 A CN 114599368A
Authority
CN
China
Prior art keywords
compound
cancer
pharmaceutically acceptable
acceptable salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080069508.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·宋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senhwa Biosciences Inc
Original Assignee
Senhwa Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc filed Critical Senhwa Biosciences Inc
Publication of CN114599368A publication Critical patent/CN114599368A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080069508.0A 2019-08-14 2020-08-14 四环化合物及其盐、组合物以及其使用方法 Pending CN114599368A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962886621P 2019-08-14 2019-08-14
US62/886,621 2019-08-14
US201962946774P 2019-12-11 2019-12-11
US62/946,774 2019-12-11
PCT/US2020/046329 WO2021030671A1 (en) 2019-08-14 2020-08-14 Tetracyclic compounds and their salts, compositions, and methods for their use

Publications (1)

Publication Number Publication Date
CN114599368A true CN114599368A (zh) 2022-06-07

Family

ID=74568302

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080069508.0A Pending CN114599368A (zh) 2019-08-14 2020-08-14 四环化合物及其盐、组合物以及其使用方法

Country Status (12)

Country Link
US (1) US20210046071A1 (https=)
EP (1) EP4013421A4 (https=)
JP (1) JP7566010B2 (https=)
KR (1) KR20220130085A (https=)
CN (1) CN114599368A (https=)
AU (1) AU2020328590B2 (https=)
BR (1) BR112022002784A2 (https=)
CA (1) CA3151112A1 (https=)
IL (1) IL290626A (https=)
PH (1) PH12022550360A1 (https=)
TW (1) TW202114694A (https=)
WO (1) WO2021030671A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7017509B2 (ja) 2015-11-20 2022-02-08 センワ バイオサイエンシズ インコーポレイテッド がんを治療するための四環式キノロン類似体の併用療法
CN112334133A (zh) 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法
CN114409681A (zh) * 2022-03-18 2022-04-29 信义核新(北京)生物科技有限公司 用于治疗dna损伤修复缺陷肿瘤的喹诺酮类似物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143737A1 (en) * 2015-11-20 2017-05-25 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928100B2 (en) * 2007-10-05 2011-04-19 Cylene Pharmaceuticals, Inc. Quinolone analogs and methods related thereto
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
ES2754207T3 (es) * 2013-11-28 2020-04-16 Tel Hashomer Medical Res Infrastructure & Services Ltd Inhibidores de la ARN polimerasa I y usos de los mismos
US9957282B2 (en) * 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
JP2018537486A (ja) * 2015-12-14 2018-12-20 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
CN112334133A (zh) * 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143737A1 (en) * 2015-11-20 2017-05-25 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer

Also Published As

Publication number Publication date
WO2021030671A1 (en) 2021-02-18
JP2022544559A (ja) 2022-10-19
US20210046071A1 (en) 2021-02-18
IL290626A (en) 2022-04-01
JP7566010B2 (ja) 2024-10-11
AU2020328590A1 (en) 2022-03-10
PH12022550360A1 (en) 2023-02-27
KR20220130085A (ko) 2022-09-26
AU2020328590B2 (en) 2026-03-26
EP4013421A1 (en) 2022-06-22
EP4013421A4 (en) 2023-08-23
TW202114694A (zh) 2021-04-16
CA3151112A1 (en) 2021-02-18
BR112022002784A2 (pt) 2022-08-09

Similar Documents

Publication Publication Date Title
US20220088029A1 (en) Combination therapy of tetracyclic quinolone analogs for treating cancer
US11524012B1 (en) Quinolone analogs and their salts, compositions, and method for their use
KR20180054657A (ko) Dna 손상제 및 atr 저해제의 병용물을 사용한 암 치료 방법
JP7566010B2 (ja) 四環式化合物及びそれらの塩、組成物、ならびにそれらの使用方法
CN114599371A (zh) 作为癌症靶向药物载体的磷脂醚缀合物
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
WO2021154976A1 (en) Methods of treating brain cancer with panobinostat
US20210046082A1 (en) Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
CN114746093A (zh) 治疗血管畸形的方法
CN117794523A (zh) 使用parp抑制剂和plk1抑制剂的癌症治疗
RU2786570C2 (ru) Комбинированная терапия тетрациклическими аналогами хинолона для лечения рака
EA052190B1 (ru) Комбинация конъюгата антитела и лекарственного средства и селективного ингибитора parp1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination